 |
INVESTOR HOME
PRESS RELEASES
PRODUCT DEMONSTRATIONS
EVENTS & WEBCASTS
ANNUAL MEETING
INVESTOR KIT
INFORMATION REQUEST
FAQs
|
|
2004 PRESS RELEASE ARCHIVE
December 13, 2004
ADVENTRX Pharmaceuticals Announces Senior Management Appointments
December 1, 2004
ADVENTRX Pharmaceuticals to Present at Vaccines Conference
November 15, 2004
ADVENTRX Pharmaceuticals Announces Third Quarter 2004 Results
November 3, 2004
ADVENTRX Pharmaceuticals to Present at CIBC World Markets 15th Annual Healthcare Conference
November 2, 2004
FDA Clears CoFactor™ to Begin Second Stage of Phase II Clinical Trial for Metastatic Colorectal Cancer
October 22, 2004
ADVENTRX Pharmaceuticals to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
October 14, 2004
CoFactor™ Granted Orphan Drug Status in the European Union for Pancreatic Cancer
October 11, 2004
ADVENTRX Pharmaceuticals to Present at the BIO Emerging Company Investor Forum
October 5, 2004
ADVENTRX Pharmaceuticals' Drug CoFactor™ Granted U.S. Orphan Drug Status by the FDA for Pancreatic Cancer
October 1, 2004
ADVENTRX Pharmaceuticals Announces CoFactor™ Results Showing Antitumor Activity with Lower Systemic Toxicity in a Colorectal Cancer Model
September 8, 2004
ADVENTRX Board of Directors Appoints Evan Levine President and CEO
August 10, 2004
ADVENTRX Pharmaceuticals Announces Second Quarter 2004 Results
July 22, 2004
ADVENTRX Pharmaceuticals Completes Move to New Facility
July 7, 2004
ADVENTRX Pharmaceuticals Initiates European Sites for its CoFactor Phase II Clinical Study
June 28, 2004
ADVENTRX Pharmaceuticals Presents Positive CoFactor™ Results in Pancreatic Tumor Model
June 21, 2004
ADVENTRX Pharmaceuticals to Present at American Stock Exchange Annual Online Healthcare & Biotech Investor Conference
June 14, 2004
ADVENTRX Pharmaceuticals Plans Expansion and Move to New Facility
June 07, 2004
ADVENTRX Pharmaceuticals Announces Positive Findings for Combination CoFactor™, VEGF antibody and 5-FU in Colorectal Tumor Model
June 1, 2004
ADVENTRX Pharmaceuticals Commences cGMP Manufacturing of Thiovir™
May 12, 2004
ADVENTRX Pharmaceuticals Reports Filing of Quarterly Report with the SEC and First Quarter 2004 Results
May 06, 2004
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Techvest Global Healthcare Conference
May 04, 2004
First Patients Dosed with CoFactor™ in U.S. Phase II Clinical Trial for Metastatic Colorectal Cancer
April 29, 2004
American Stock Exchange Lists Common Stock Of Adventrx Pharmaceuticals, Inc.
April 27, 2004
ADVENTRX Pharmaceuticals To Be Listed On AMEX
April 26, 2004
ADVENTRX Pharmaceuticals to Webcast Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
April 19, 2004
ADVENTRX Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
April 15, 2004
ADVENTRX Pharmaceuticals Receives FDA Clearance for HIV Viral Entry Inhibitor to Begin Phase Ib/IIa Human Clinical Trial
April 5, 2004
ADVENTRX Pharmaceuticals Announces Definitive Agreement for Sale of Common Stock
March 11, 2004
ADVENTRX Pharmaceuticals Adds Vice President of Clinical and Medical Affairs to Expand Clinical Trial Efforts
March 4, 2004
ADVENTRX Pharmaceuticals Files IND for Phase Ib/IIa Trials for HIV Viral Entry Inhibitor
February 24, 2004
ADVENTRX Pharmaceuticals Expands Scientific Advisory Board
February 20, 2004
ADVENTRX Pharmaceuticals Announces Notice of Government Grant Received by M.D. Anderson Cancer Center
February 17, 2004
ADVENTRX Pharmaceuticals Elects New Member to the Board Of Directors
February 5, 2004
ADVENTRX Pharmaceuticals Appoints Dr. Mark J. Cantwell Director of Preclinical Programs
February 3, 2004
ADVENTRX Pharmaceuticals Announces Patent Granted for Eradicaide™ Technology to Diagnose, Prevent and Treat AIDS
January 29, 2004
ADVENTRX Pharmaceuticals Elects Two New Members to the Board of Directors
|
|
|
